Request Demo
Recent blog posts
Latest Hotspot
8 min read
Alpha-mannosidosis Indication Strategy Report 2026: MAN2B1, Trials and Deals
23 July 2026
2026 Alpha-mannosidosis strategy: epidemiology, MAN2B1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Mucolipidosis II Indication Strategy Report 2026: GNPTAB, Trials and Deals
23 July 2026
2026 Mucolipidosis II strategy: epidemiology, GNPTAB biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Mucopolysaccharidosis type IX Indication Strategy Report 2026: HYAL1, Trials and Deals
23 July 2026
2026 Mucopolysaccharidosis type IX strategy: epidemiology, HYAL1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Mucopolysaccharidosis type VII Indication Strategy Report 2026: GUSB, Trials and Deals
23 July 2026
2026 Mucopolysaccharidosis type VII strategy: epidemiology, GUSB biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type IX Indication Strategy Report 2026: PHKA2, Trials and Deals
23 July 2026
2026 Glycogen storage disease type IX strategy: epidemiology, PHKA2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type VII Indication Strategy Report 2026: PFKM, Trials and Deals
23 July 2026
2026 Glycogen storage disease type VII strategy: epidemiology, PFKM biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type V Indication Strategy Report 2026: PYGM, Trials and Deals
23 July 2026
2026 Glycogen storage disease type V strategy: epidemiology, PYGM biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type IV Indication Strategy Report 2026: GBE1, Trials and Deals
23 July 2026
2026 Glycogen storage disease type IV strategy: epidemiology, GBE1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type III Indication Strategy Report 2026: AGL, Trials and Deals
23 July 2026
2026 Glycogen storage disease type III strategy: epidemiology, AGL biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Small fiber neuropathy Indication Strategy Report 2026: Nav1.7, Trials and Deals
23 July 2026
2026 Small fiber neuropathy strategy: epidemiology, Nav1.7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chemotherapy-induced peripheral neuropathy Indication Strategy Report 2026: Nav1.7, Trials and Deals
23 July 2026
2026 Chemotherapy-induced peripheral neuropathy strategy: epidemiology, Nav1.7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Complex regional pain syndrome Indication Strategy Report 2026: NGF, Trials and Deals
23 July 2026
2026 Complex regional pain syndrome strategy: epidemiology, NGF biology, clinical competition, recent deals, unmet need and market attractiveness.